Bellevue Group AG Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001674546

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 153 positions · Total reported value $4.82B · Top-10 concentration 47.1% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 59.4% · 22 new · 62 cut · 17 exited

Active Share (vs S&P 500): 94.3% · vs QQQ: 96.4% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Bellevue Group AG disclosed 153 equity positions with a combined reported value of $4.82B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were AMGN ($363.21M), GILD ($320.56M), VRTX ($302.46M). By sector, the heaviest allocations are Health Care 97.7%, Industrials 1.6%. Versus the prior quarter, allocation shifted toward Health Care (+5.2pp) and away from Other (-4.8pp).

Versus the prior quarter, Bellevue Group AG opened 22 new positions, trimmed 62 and fully exited 17, a turnover rate of 59.4% of positions. The portfolio's overlap with the prior quarter was 77% of names.

The largest new positions opened in Q3 2026 were KOD ($43.65M), ANRO ($29.71M), LBRX ($27.46M).

Of the 17 positions fully exited versus the prior quarter, the largest were NUVL ($130.08M), CRNX ($98.04M), RARE ($66.20M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • KOD KODIAK SCIENCES INC · $43.65M
  • ANRO ALTO NEUROSCIENCE INC · $29.71M
  • LBRX LB PHARMACEUTICALS INC · $27.46M
  • EPRX EUPRAXIA PHARMACEUTICALS INC · $23.62M
  • DARE YARROW BIOSCIENCE INC · $22.52M
  • BCAX BICARA THERAPEUTICS INC · $13.41M
  • ROIV ROIVANT SCIENCES LTD · $3.07M
  • GH GUARDANT HEALTH INC · $1.11M

Fully Exited (vs previous quarter)

  • NUVL NUVALENT INC · prev qtr: $130.08M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $98.04M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $66.20M
  • CLDX CELLDEX THERAPEUTICS INC NEW · prev qtr: $44.65M
  • GLUE MONTE ROSA THERAPEUTICS INC · prev qtr: $28.80M
  • ANNX ANNEXON INC · prev qtr: $23.41M
  • PODD INSULET CORP · prev qtr: $19.41M
  • MOH MOLINA HEALTHCARE INC · prev qtr: $6.35M

Insider Transactions (Form 4)

Latest Bellevue Group AG buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Bellevue Group AG files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 153 positions worth $4.82B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 153 positions · $4.82B reported value (Q3 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: AMGN (AMGEN INC) at 7.5%
  • Average position size: $31.50M

Sector Tilt

  • Health Care 97.7%
  • Industrials 1.6%
  • Information Technology 0.5%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 22 new, 42 added, 62 reduced, 17 exited
  • 27 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is bullish on Health Care, increasing exposure to biotech/pharma names (e.g., AMGN, REGN, BIIB) while trimming some positions (ARGX, RVMD, ORKA), suggesting a selective growth focus within the sector. 2. Key moves: - Added: AMGN (shares +1.2%), REGN (shares +77.8%), INSM (+8.2%), VRDN (+5.6%), BIIB (new position, +176,800% QoQ). - Reduced: ARGX (shares -3.5%), RVMD (-4.7%), ORKA (-1.0%). 3. Portfolio structure: Highly active, concentrated in Health Care (100% of top 10), with high risk appetite (e.g., BIIB’s massive new position, ORKA’s volatility). 4. Per-holding one-liner: - AMGN: Biotech giant (unverified). - GILD: HIV drug developer (unverified). - VRTX: Cystic fibrosis treatments (unverified). - ARGX: Autoimmune disease therapies (unverified). - REGN: Ophthalmology/immunology drugs (unverified). - RVMD: Cancer-focused biotech (unverified). - INSM: Rare lung disease treatments (unverified). - VRDN: Thyroid eye disease drug (unverified). - ORKA: Oncology biotech (unverified). - BIIB: Neurodegenerative disease drugs (unverified). 5. Style summary: Aggressive Health Care tilt, favoring high-growth biotech/pharma with selective trimming and new bold bets.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:42

Sector Allocation

Health Care 97.7%
Technology 0.5%
Other 0.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 861.69K $363.21M 7.54%
7.54%
Add
2 2.15M $320.56M 6.65%
6.65%
Hold
3 578.53K $302.46M 6.28%
6.28%
Hold
4 290.51K $278.57M 5.78%
5.78%
Reduce
5 279.59K $212.00M 4.40%
4.40%
Add
6 998.95K $205.04M 4.25%
4.25%
Reduce
7 1.51M $172.13M 3.57%
3.57%
Add
8 7.11M $146.38M 3.04%
3.04%
Add
9 1.64M $136.68M 2.84%
2.84%
Reduce
10 597.92K $135.06M 2.80%
2.80%
Add
11 2.79M $134.66M 2.79%
2.79%
Add
12 2.32M $132.14M 2.74%
2.74%
Add
13 6.19M $111.66M 2.32%
2.32%
Hold
14 1.05M $103.57M 2.15%
2.15%
Add
15 186.43K $101.02M 2.10%
2.10%
Reduce
16 248.00K $100.85M 2.09%
2.09%
Reduce
17 1.04M $90.03M 1.87%
1.87%
Add
18 1.20M $78.74M 1.63%
1.63%
Add
19 2.26M $68.59M 1.42%
1.42%
Reduce
20 1.47M $67.34M 1.40%
1.40%
Reduce
21 741.88K $64.02M 1.33%
1.33%
Reduce
22 4.29M $60.33M 1.25%
1.25%
Add
23 490.42K $59.51M 1.24%
1.24%
Add
24 240.32K $59.30M 1.23%
1.23%
Add
25 185.37K $51.05M 1.06%
1.06%
Reduce
26 587.73K $50.73M 1.05%
1.05%
Reduce
27 247.73K $45.68M 0.95%
0.95%
Add
28 64.75K $43.71M 0.91%
0.91%
Reduce
29 460.42K $43.65M 0.91%
0.91%
New
30 1.92M $40.84M 0.85%
0.85%
Add
31 1.35M $38.46M 0.80%
0.80%
Hold
32 206.79K $37.02M 0.77%
0.77%
Add
33 560.00K $36.66M 0.76%
0.76%
Hold
34 827.68K $36.13M 0.75%
0.75%
Reduce
35 2.11M $35.74M 0.74%
0.74%
Add
36 97.11K $35.65M 0.74%
0.74%
Reduce
37 493.60K $34.99M 0.73%
0.73%
Hold
38 379.87K $33.82M 0.70%
0.70%
Add
39 61.49K $32.11M 0.67%
0.67%
Hold
40 27.48K $31.80M 0.66%
0.66%
Reduce
41 143.47K $31.72M 0.66%
0.66%
Reduce
42 1.16M $29.71M 0.62%
0.62%
New
43 715.51K $27.46M 0.57%
0.57%
New
44 1.10M $27.42M 0.57%
0.57%
Add
45 76.00K $25.27M 0.52%
0.52%
Reduce
46 2.60M $23.62M 0.49%
0.49%
New
47 85.83K $22.72M 0.47%
0.47%
Reduce
48 347.19K $22.70M 0.47%
0.47%
Add
49 1.00M $22.52M 0.47%
0.47%
New
50 1.10M $22.19M 0.46%
0.46%
Hold

FAQ

What did Bellevue Group AG buy in 2026-Q3?

In its 2026-Q3 13F filing, Bellevue Group AG reported 153 equity positions worth $4.82B in aggregate; its largest disclosed positions were AMGN ($363.21M), GILD ($320.56M), VRTX ($302.46M).

How large is Bellevue Group AG's portfolio?

Bellevue Group AG reported $4.82B of long equity holdings across 153 positions as of 2026-Q3. Top-10 holdings account for 47.1% of reported value.

What is Bellevue Group AG's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bellevue-group-ag/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →